US FDA explains need for labelling change following new safety info
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has issued draft guidance explaining how it is implementing its authority under the FDA Amendments Act of 2007 to require and, if necessary, order companies to make labelling changes to approved prescription drugs and biologics when new safety related information becomes available1,2.